Does insulin resistance lower SHBG but fail to raise free androgens when ovarian or adrenal androgen production is low?

Research into the relationship between metabolic health and hormonal status confirms that insulin resistance is a primary driver of sex hormone-binding globulin (SHBG) suppression. However, the final "free" androgen level is determined by the balance between hepatic binding protein production and the output of the ovaries and adrenals.

Clinical and mechanistic evidence

The link between insulin and SHBG is robust and well-documented across multiple clinical populations.

• Insulin-driven SHBG suppression: High insulin levels directly suppress hepatic SHBG production. Mechanistically, insulin promotes de novo lipogenesis, which reduces levels of hepatocyte nuclear factor 4-alpha (HNF-4α), a key transcription factor for the SHBG gene. This relationship is highly consistent; studies in women with PCOS and metabolic syndrome show that fasting insulin and HOMA-IR are among the strongest predictors of low SHBG.
• Increased free fraction: SHBG serves as the primary transport protein for sex steroids. When SHBG levels fall, the percentage of "free" or bioavailable testosterone rises, often increasing the Free Androgen Index (FAI) even if total testosterone remains stable. In typical PCOS, this results in a high-androgen biochemical profile.

Blunting of hyperandrogenism

The expected increase in free androgens can be blunted or negated if total androgen production is low.

• Androgen production deficit: In conditions such as primary ovarian insufficiency (POI), surgical menopause, or adrenal insufficiency (Addison’s disease), the absolute output of androgens (testosterone, DHEA, and androstenedione) is significantly reduced.
• Mathematical balance: The biochemical pattern of free hormone levels is a ratio. If the reduction in total androgen production (the numerator) is more severe than the reduction in SHBG (the denominator), the free androgen index will remain low or normal.
• Metabolic feedback: In perimenopausal or postmenopausal women, the loss of estrogen can lead to increased visceral adiposity and insulin resistance. While this metabolic shift lowers SHBG, the concomitant decline in ovarian androgen production often prevents the development of the high free androgen levels seen in younger, insulin-resistant women.

Mechanistic pathways

• HNF-4α regulation: Insulin’s suppression of SHBG is mediated by its effect on hepatic lipids rather than a direct inhibitory effect on the SHBG promoter. This explains why SHBG is considered a sensitive marker of liver fat and insulin sensitivity.
• Bidirectional feedback: While insulin lowers SHBG to increase free androgens, elevated free androgens can further worsen insulin resistance by promoting adipose tissue dysfunction, creating a circular metabolic-hormonal loop.

Bottom line

In insulin-resistant states, low SHBG typically signals high free androgen exposure. However, if ovarian or adrenal production is compromised—as seen in ovarian failure or adrenal insufficiency—this hyperandrogenic pattern is blunted, leading to low or normal free androgen levels despite the low SHBG. This highlights that SHBG is more accurately viewed as a metabolic marker of insulin status than a definitive predictor of androgenic state.